Skip to main content
. 2016 Jun 29;52(2):218–228. doi: 10.1007/s00535-016-1230-0

Fig. 1.

Fig. 1

Subgroup analysis of total patients with either biliary tract carcinoma (BTC) or intrahepatic (Ih) cholangiocarcinoma (CC), patients with benign biliary tract disease (BD), and control subjects (controls) in terms of the positivity of WFA-sialylated MUC1 (WFA-MUC1) and CA19-9 in serum samples (upper panel) and bile samples (lower panel)